Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy
PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS: Read More
Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses
PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub Read More
Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer
PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub Read More
Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan
PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Read More
A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response
PUBLICATION: Breast Cancer Res Treat (2012) 133: 37. https://doi.org/10.1007/s10549-011-1683-z. AUTHORS: Read More
Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance
PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub Read More
The 70-gene Prognosis-Signature Predicts Disease Outcome in Breast Cancer Patients with 1-3 Positive Lymph Nodes in an Independent Validation Study
PUBLICATION: Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2. Epub Read More
